LXRX vs MLYS
LXRX: An early-stage commercial biopharmaceutical company with a gene-discovery platform advancing cardiovascular and metabolic therapies, headlined by commercialized INPEFA and Phase 3 hypertrophic cardiomyopathy candidate sotagliflozin. MLYS: Mineralys is a clinical-stage biopharmaceutical company pursuing FDA approval of lorundrostat, a selective aldosterone synthase inhibitor targeting resistant hypertension and related cardiorenal diseases.
Side-by-side fundamentals
| Metric | LXRX | MLYS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.25 | $27.01 | |
| Market cap as of 2026-07-23 | $1.0B | $2.4B | |
| Net margin as of 2026-07-23 | -37.5% | n/a | |
| Gross margin as of 2026-07-23 | +99.5% | n/a | |
| Operating margin as of 2026-07-23 | -34.8% | n/a | |
| ROE as of 2026-07-23 | -18.6% | -27.9% | LXRX higher |
| ROA as of 2026-07-23 | -11.8% | -27.0% | LXRX higher |
| Debt / equity as of 2026-07-23 | 0.24 | 0.00 | MLYS lower |
| Revenue growth (YoY) as of 2026-07-23 | +123.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +610.3% | n/a | |
| Beta as of 2026-07-23 | 1.03 | 0.59 | |
| 1-year return as of 2026-07-22 close | +87.5% | +102.1% | MLYS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.